Mealey's (June 18, 2018, 11:28 AM EDT) -- ATLANTA — Efforts by Solvay Pharmaceuticals Inc. to obtain summary judgment on claims by the Federal Trade Commission that Solvay violated antitrust laws with reverse payments designed to prevent entry to the market of generic AndroGel were unsuccessful June 14, when a Georgia federal judge overseeing multidistrict litigation found that the government has adequately pleaded that Solvay conspired to restrain trade (In re: AndroGel Antitrust Litigation No. II, MDL No. 2084 [All Cases], No. 1:09-md-2084, N.D. Ga., 2018 U.S. Dist. LEXIS 99716)....